Skip to main content
SpringerLink
Log in

HLA-B*13:01 screening not cost effective prior to cotrimoxazole use

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Cost-effectiveness analysis of HLA-B*13:01 screening for the prevention of co-trimoxazole-induced severe cutaneous adverse reactions among HIV-infected patients in Thailand Journal of Medical Economics : 13 Oct 2023. Available from: URL: https://doi.org/10.1080/13696998.2023.2270868

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

HLA-B*13:01 screening not cost effective prior to cotrimoxazole use. Reactions Weekly 1979, 8 (2023). https://doi.org/10.1007/s40278-023-47735-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-47735-x

Search

Navigation